Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
International Review of Neurobiology
|
August 29, 2020
A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
Russell Esterline, Jan Oscarsson, Jeffrey Burns
International Review of Neurobiology
|
August 3, 2020
Preface
Grażyna Söderbom, Russell Esterline, Jan Oscarsson, et al.
International Review of Neurobiology
|
August 29, 2020
Preface
Grażyna Söderbom, Russell Esterline, Jan Oscarsson, et al.
The Lancet. Diabetes & Endocrinology
|
December 18, 2021
Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply
Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 24, 2018
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes
Per Lundkvist, Maria J Pereira, Prasad G Kamble, et al.
Therapeutic Innovation & Regulatory Science
|
June 14, 2022
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
Samvel B Gasparyan, Joan Buenconsejo, Elaine K Kowalewski, et al.
Diabetologia
|
April 11, 2025
Alterations in cerebral perfusion and substrate metabolism in type 2 diabetes: interactions with APOE-ε4
Martin Schain, Edvin Johansson, Iina Laitinen, et al.
International Journal of Molecular Sciences
|
July 27, 2022
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
Elmar Zügner, Hsiu-Chiung Yang, Petra Kotzbeck, et al.
Cardiovascular Diabetology
|
November 16, 2024
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Sven O Göpel, Damilola Adingupu, Jue Wang, et al.
Diabetes Care
|
April 16, 2021
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
Yvo J M Op den Kamp, Marlies de Ligt, Bas Dautzenberg, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
International Review of Neurobiology
|
August 29, 2020
A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
Russell Esterline, Jan Oscarsson, Jeffrey Burns
International Review of Neurobiology
|
August 3, 2020
Preface
Grażyna Söderbom, Russell Esterline, Jan Oscarsson, et al.
International Review of Neurobiology
|
August 29, 2020
Preface
Grażyna Söderbom, Russell Esterline, Jan Oscarsson, et al.
The Lancet. Diabetes & Endocrinology
|
December 18, 2021
Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply
Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 24, 2018
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes
Per Lundkvist, Maria J Pereira, Prasad G Kamble, et al.
Therapeutic Innovation & Regulatory Science
|
June 14, 2022
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
Samvel B Gasparyan, Joan Buenconsejo, Elaine K Kowalewski, et al.
Diabetologia
|
April 11, 2025
Alterations in cerebral perfusion and substrate metabolism in type 2 diabetes: interactions with APOE-ε4
Martin Schain, Edvin Johansson, Iina Laitinen, et al.
International Journal of Molecular Sciences
|
July 27, 2022
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
Elmar Zügner, Hsiu-Chiung Yang, Petra Kotzbeck, et al.
Cardiovascular Diabetology
|
November 16, 2024
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Sven O Göpel, Damilola Adingupu, Jue Wang, et al.
Diabetes Care
|
April 16, 2021
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
Yvo J M Op den Kamp, Marlies de Ligt, Bas Dautzenberg, et al.
Page
of 3